A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

February 13, 2021

Study Completion Date

February 13, 2021

Conditions
COVIDCovid-19CoronavirusCoronavirus InfectionSevere Acute Respiratory SyndromeSevere Acute Respiratory Syndrome Coronavirus 2Sars-CoV2ArdsAcute Respiratory Distress Syndrome
Interventions
DRUG

APL-9

Complement (C3) Inhibitor

OTHER

Vehicle Control

Normal saline of equal volume to active arm

Trial Locations (24)

10032

Columbia University, New York

14203

University at Buffalo, Buffalo

32250

Baptist Medical Center Beaches, Jacksonville Beach

40207

Norton Women's and Children's Hospital, Louisville

40217

Norton Audobon Hospital, Louisville

40241

Westchester General Hospital, Miami

46804

Lutheran Health Physicians, Fort Wayne

48075

Ascension Providence Hospital, Southfield

52242

University of Iowa Hospitals and Clinics, Iowa City

60153

Loyola University Medical Center, Maywood

60611

Northwestern University, Feinberg School of Medicine, Chicago

71301

Cambridge Medical Trials, Alexandria

76508

Texas A&M College of Medicine - Scott and White, Temple

93701

University of California at San Francisco - Fresno, Fresno

94115

California Pacific Medical Center, San Francisco

08903

Rutgers University - Robert Wood Johnson Medical School, New Brunswick

83430-000

Hospital Angelina Caron, Campina Grande do Sul

90020-090

Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre

91530-001

Hospital São Lucas da PUCRS, Porto Alegre

18618-686

UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP, Botucatu

09190-615

Hospital Estadual Mario Covas, Santo André

0917-090

CEMEC - Centro Multidisciplinar de Estudos Clinicos LTDA EPP, São Bernardo do Campo

01323-020

Hospital Alemao Oswaldo Cruz, São Paulo

08270-120

Hospital Santa Marcelina, São Paulo

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY